Myeloma UK are passionate about ensuring patients have access to the treatments that are right for them. As a result, one of the aims of a recent project in our Health Services Research Programme was to understand how myeloma patients choose between different treatment options and identify what treatment attributes are most important to them.…
Following the cancellation of the British Society for Haematology 60th Annual Scientific Meeting, due to take place this week, the British Journal of Haematology have released all accepted abstracts as a supplement to the most recent issue. You can access the abstract list here. Our two abstracts, which outline our Clinical Service Excellence Programme and…
All myeloma patients have been advised to shield for 12 weeks to protect themselves from COVID-19. At Myeloma UK, we recognise this may cause psychological and emotional stress for many patients and their families and those with related conditions. Our Myeloma Infoline (0800 980 3332, UK or 1800 937 773, Ireland) and Ask the Nurse…
During the COVID-19 pandemic, healthcare professionals looking after myeloma patients face important and difficult decisions about the best way to treat their patients, whilst minimising their risk of infection. Several myeloma specialists have been sharing their experience as they work together to consider the safest and most effective ways to manage this vulnerable group of patients. Here we have compiled a short list of informative webinars, podcasts and articles to keep…
Myeloma UK have developed an information hub to help keep patients up to date with the latest news on COVID-19. The COVID-19 Information Hub is a one stop shop for information about the COVID-19 pandemic and how it is affecting patients’ treatment and care. The Hub is being regularly updated with the latest news and guidance from the UK Government…
The response to the COVID-19 pandemic has put the UK Government and NHS on an emergency footing. With this substantial change to NHS services, there has been a rapid growth in published guidelines and policy to help Healthcare Professionals (HCPs) ensure patients get the right treatment and care. Here we have detailed some key sources…
The 61st American Society of Hematology Annual Meeting (ASH) took place on 7-10 December in Orlando, Florida. It was attended by over 30,000 scientists and clinicians from around the world and covered around 6,000 topics with over 700 myeloma abstracts. Here are some of our highlights from this year’s meeting. Myeloma XI There were five…
Pathologists and pathology labs play a critical role in diagnosis and the ongoing monitoring of myeloma patients. Like many areas of the NHS, they have been under increasing pressure to provide a consistent, high standard service over the years. To help alleviate some of the pressure in pathology services and provide good practice recommendations that…
The 61st American Society of Hematology Annual Meeting (ASH) took place on 7-10 December in Orlando, Florida. Our Director of Research Sarah McDonald and Director of Healthcare Advocacy Services Ira Laketic-Ljubojevic attended to learn about the latest myeloma research and see the progress from Myeloma UK funded research. Results from research part-funded by Myeloma UK, the…
The way evidence is used to approve new treatments for use on the NHS is set to change, under a review being carried out by the National Institute for Health and Care Excellence (NICE). The review of methods, running throughout 2020, is an opportunity to address some of the challenges in approving treatments: for example, ensuring…
